Castle Biosciences Reports Q3 Revenue of $102.9 Million, Raises 2026 Guidance
Q3 2026 revenue rose 24% year over year, while TissueCypher test report volume increased 47%. Castle Biosciences raised full-year 2026 revenue guidance to $385–395 million, from a prior range.
Story updates
09:06:39 PM UTC
SquawkNews
Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% year over year, and raised 2026 revenue guidance to $385—395M from $365—375M. It maintained its expectation for positive Adjusted EBITDA in Q4 2026 and full-year 2026 and 2027.Material DetailsContext by AI AnalystThis is a quarterly ope…
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025TissueCypher® test report volume increased 47% over Q3 2025Raising full-year 2026 revenue guidance to $385-395 million from $365-375 millionConference call and webcast today at 4:30 p.m. ETFRIENDSWOOD, Texas, Nov. 5, 2026…